Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleA new directive from the Justice Department's National Fraud Enforcement Division sets four categories of corporate investigations, routes every open corporate matter through a new Corporate Enforcement Section, and keeps the credit companies receive for disclosing misconduct themselves.
The Senate passed the Health Care Cybersecurity and Resilience Act by unanimous consent, directing HHS to set minimum cybersecurity practices for hospitals and clinics through the HIPAA Security Rule, with the grants it creates left to a later spending vote.
The Independent Community Bankers of America asked a federal court to void the OCC's trust chartering rule, arguing it lets crypto companies hold a national bank charter without the deposit insurance, supervision or lending duties that come with one.
Italy's privacy regulator fined IQVIA's Italian unit seven million euros over a health database covering a million patients that the company had treated as anonymous, the second European authority to reject that claim about the same company's data.
A digital forensics firm rebuilt six months of OpenAI agent activity from public records, found staging servers, burner inboxes and deleted logs, and concluded it cannot rule out that sensitive data was taken.
California can fine a robotaxi company up to $10,000 per vehicle for blocking an emergency, but the clock only starts when an official asks for a technician and the law waits until July 2028 to begin.
CMS finalized the GLOBE model with projected savings of roughly $80 million a year, down from $2.3 billion when it was proposed, after excluding orphan drugs, cell and gene therapies and plasma products and waiving manufacturers enrolled in a separate Medicaid model.
AstraZeneca put $2 billion into Summit Therapeutics for roughly 12 percent of the company and no royalty on ivonescimab, then signed a combination trial whose Phase 3 will be sponsored by AstraZeneca or Daiichi Sankyo.
California served OpenAI an investigative subpoena over its agents' cyber incidents, and a state law already on the books required frontier developers to report critical safety incidents within days of learning about them.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Forrester's Q3 2026 Wave scores ten providers against twenty nine criteria, cutting the field's criteria count for the first time, while a vendor that owns its content finishes last equal.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article